Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers
Open accessThe DOI matches its Crossref record.
Abstract
OBJECTIVES: The WHO recommends artemisinin-based combination therapies for treatment of uncomplicated falciparum malaria. At least 15 African countries have adopted artesunate plus amodiaquine as treatment policy. As no pharmacokinetic data on this combination have been published to date, we investigated its pharmacokinetic interactions and tolerability in healthy volunteers in Africa. METHODS: In a randomized, three-phase, cross-over study, amodiaquine (10 mg/kg) and artesunate (4 mg/kg) were given as single oral doses to 15 healthy volunteers. Artesunate was given to all volunteers on day 0. On day 7 they received either amodiaquine or amodiaquine plus artesunate and the alternative regimen on day 28. The pharmacokinetics of artesunate and amodiaquine and their main active metabolites dihydroartemisinin and desethylamodiaquine were compared following monotherapy and combination therapy using analysis of variance. RESULTS: Thirteen volunteers completed the study, and pharmacokinetic parameters could be determined for twelve volunteers. When given in combination, the mean AUC was lower for dihydroartemisinin [ratio 67% (95% CI 51-88%); P = 0.008] and desethylamodiaquine [ratio 65% (95% CI 46-90%); P = 0.015] when compared with monotherapy. Adverse events of concern occurred in four volunteers (27%): grade 3 transaminitis (n = 1), neutropaenia (n = 2), and hypersensitivity (n = 1). CONCLUSION: The total drug exposure to both drugs was reduced significantly when they were given in combination. The clinical significance of these interactions is unclear and must be studied in malaria patients. The frequency and nature of adverse events among the healthy volunteers were of concern, and suggest laboratory monitoring would be needed in malaria patients treated with artesunate plus amodiaquine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Si, L., Bai, H., Rodas, M., Cao, W., Oh, C. Y., Jiang, A., Moller, R., Hoagland, D., Oishi, K., Horiuchi, S., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00718-9 · Cited by 440
Charman, S. A., Arbe-Barnes, S., Bathurst, I. C., Brun, R., Campbell, M., Charman, W. N., Chiu, F. C. K., Chollet, J., Craft, J. C., Creek, D. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015762108 · Cited by 373
Morris, C. A., Duparc, S., Borghini-Fuhrer, I., Jung, D., Shin, C.-S., & Fleckenstein, L. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-263 · Cited by 232
Faucher, J., Aubouy, A., Adeothy, A., Cottrell, G., Doritchamou, J., Gourmel, B., Houzé, P., Kossou, H., Amedome, H., Massougbodji, A., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/599378 · Cited by 61
Tarning, J., Chotsiri, P., Jullien, V., Rijken, M. J., Bergstrand, M., Cammas, M., McGready, R., Singhasivanon, P., Day, N. P. J., White, N. J., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01242-12 · Cited by 51
Rijken, M. J., McGready, R., Jullien, V., Tarning, J., Lindegardh, N., Phyo, A. P., Win, A. K., Hsi, P., Cammas, M., Singhasivanon, P., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00154-11 · Cited by 50
Malaria – Current Treatment Options
Virginia, D. M., Shegokar, R., & Pathak, Y. (2023) · Malarial Drug Delivery Systems · doi:10.1007/978-3-031-15848-3_4 · Cited by 1
Metadata
- Authors
- Orrell, C., Little, F., Smith, P., Folb, P., Taylor, W., Olliaro, P., & Barnes, K. I.
- Venue
- European Journal of Clinical Pharmacology
- Published
- 2008-04-16
- Volume
- 64
- Issue
- 7
- Pages
- 683-690
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W2110456860
- Cited by
- 91
- References
- 0
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.